Recent Updates
Recently added Catalysts
TEVA Positive Sentiment

Teva to Present at the 9th Annual Evercore Healthcare Conference, the Piper Sandler 38th Annual Healthcare Conference and Citi’s 2026 Global Healthcare Conference

Key Takeaway: Teva Pharmaceutical Industries announced that CEO Richard Francis will present at three upcoming investor conferences. These include the 9th Annual Evercore Healthcare Conference on November 30, 2026, and two conferences on December 1, 2026. Live webcasts will be available on Teva's Investor Relations website.

Market Sentiment Analysis

POSITIVE FACTORS

  • Teva's CEO will present at three major healthcare conferences.
  • The company continues to focus on innovative and biosimilar medicines.
  • Teva has a long-standing commitment to bettering health.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+48%
120-day peak, hindsight
Typical move
2.6%
average across 15 past catalysts
Lead asset
TEV-56248
Phase 3 · Asthma

Full Press Release Details

TEL AVIV, Israel and PARSIPPANY, N.J., Nov. 20, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, and other members of executive management will present at three upcoming investor conferences as follows:
• 9th Annual Evercore Healthcare Conference Monday, November 30, 2026, at 1:45 PM Eastern Time (ET)
• Piper Sandler 38th Annual Healthcare Conference Tuesday, December 1, 2026, at 8:30 AM ET
• Citi’s 2026 Global Healthcare Conference Tuesday, December 1, 2026, at 9:00 AM ET
To access a live webcast of the presentation, visit Teva’s Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations.
An archived version of the webcast will be available within 24 hours after the end of the live discussion.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This Document and the presentation at the conferences may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace, including our ability to successfully execute on our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and to profitably commercialize our innovative medicines and biosimilar portfolio, whether organically or through business development, to sustain and focus our portfolio of generic medicines, and to execute on our organizational transformation and to achieve expected cost savings; our significant indebtedness; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in our Quarterly Report on Form 10-Q for the third quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned “Risk Factors” and “Forward Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

Frequently Asked Questions

When will Teva present at the Evercore Healthcare Conference?

Teva will present at the Evercore Healthcare Conference on November 30, 2026.

Who will represent Teva at the conferences?

Teva's President and CEO, Richard Francis, will represent the company.

Where can I access the live webcast of Teva's presentations?

The live webcast can be accessed on Teva's Investor Relations website.

What is Teva's focus in the biopharmaceutical industry?

Teva focuses on innovative medicines, biosimilars, and complex generics.

Last updated: Nov 20, 2026